TEL/AML1-positive pediatric leukemia: Prognostic significance and therapeutic approaches

Current Opinion in Hematology

Volumn 9, Issue 4, 2002, Pages 345-352

  Loh, Mignon L ^a   Rubnitz, Jeffrey E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; TRANSCRIPTION FACTOR ETV6; UNCLASSIFIED DRUG; ONCOPROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CHILDHOOD CANCER; FUSION GENE; GENE REARRANGEMENT; HUMAN; IMMUNE RESPONSE; LEUKEMIA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; GENETICS; METABOLISM; PHYSIOLOGY;

CHILD; HUMAN; LEUKEMIA, LYMPHOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS;

EID: 0036014993     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200207000-00013     Document Type: Review

References (66)

1. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
2. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms
3. Yolk sac angiogenic defect and intraembryonic apoptosis in mice lacking the Ets-related factor TEL
4. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
5. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
6. Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies
7. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter
8. Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9
9. The leukemia-associated gene TEL encodes a transcription represser which associates with SMRT and mSin3A
10. Recruitment of the nuclear receptor corepresser N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein
11. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein
12. Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins
13. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3
14. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots
15. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia
16. Prenatal origin of acute lymphoblastic leukaemia in children
17. Molecular tracking of leukemogenesis in a triplet pregnancy
18. Molecular analysis of single colonies reveals a diverse origin of initial clonal proliferation in B-precursor acute lymphoblastic leukemia that can precede the t(12;21) translocation
19. Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals
20. Characterization of additional genetic events in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion: A molecular cytogenetics study
21. The 12;21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia
22. The TEL-AML1 fusion accompanied by loss of the untranslocated TEL allele in B-precursor acute lymphoblastic leukaemia of childhood
23. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion
24. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia
25. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia
26. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis
27. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
28. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials
29. Outcome and lineage involvement in t(12;21) childhood acute lymphoblastic leukaemia
30. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia
31. TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia
32. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification
33. TEL/AML-1 fusion gene: Its frequency and prognostic significance in childhood acute lymphoblastic leukemia
34. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol
35. TEL/AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia
36. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong
37. Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia
38. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse
39. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia
40. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
41. TEL/AML1 positivity in childhood ALL: Average or better prognosis?
42. TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia
43. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediatric Oncology Group study
44. Acute lymphoblastic leukemia in children
45. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
46. Analysis of prognostic factors in acute lymphoblastic leukemia
47. Chemosensitivity of tel-aml1 fusion transcript positive acute lymphoblastic leukemia cells
48. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
49. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study
50. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01
51. Low incidence of TEL/AML1 fusion and TEL deletion in Korean childhood acute leukemia by extra-signal fluorescence in situ hybridization
52. Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain
53. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia
54. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood
55. Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
56. TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia
57. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: A matched-pair analysis
58. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes
59. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features
60. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Children's Cancer Group
61. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
62. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia
63. Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia
64. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia
65. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript
66. Childhood acute lymphoblastic leukaemia-current status and future perspectives